{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:27:49Z","timestamp":1785403669760,"version":"3.56.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA086862"],"award-info":[{"award-number":["P30CA086862"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>One strategy for enhancing the anticancer immune response is to inject tumors with immunostimulatory agents that modify the tumor microenvironment (TME) to induce a stronger antitumor T-cell response. In situ immunization with vidutolimod (Vidu), a virus-like particle containing a CpG-A TLR9 agonist, has demonstrated antitumor activity in preclinical and early-phase clinical studies; however its effect on tumor-specific CD8+ T cells remain poorly defined. Using the OT-1 model, we assessed how Vidu affects the activation, cytotoxicity, and antitumor activity of tumor-specific CD8+ T cells in vitro and in vivo. In vitro, Vidu reduced proliferation but increased expression of both activation and exhaustion markers. In vivo, repeated intratumoral Vidu injections induced a transient increase in the frequency of intratumoral tumor-specific CD8+ T cells and enhanced antitumor activity. The addition of \u03b1PD-1 to Vidu led to a persistent increase in intratumoral tumor-specific CD8+ T cells and sustained tumor control. Vidu treatment increased expression of markers associated with terminal exhaustion on intratumoral tumor-specific CD8+ T cells. Such treatment also increased the number of circulating tumor-specific CD8+ T cells that expressed high PD-1 but lacked coexpression of other exhaustion markers. Together, these findings demonstrate that Vidu treatment expands the number of intratumoral and circulating tumor-specific CD8+ T cells and that the number of tumor-specific CD8+ T cells and the antitumor response is sustained by the addition of \u03b1PD-1. These results support continued evaluation of Vidu as a cancer immunotherapeutic agent, including in combination with immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In situ immunization with Vidu combined with \u03b1PD-1 therapy enhances the antitumor response by tumor-specific CD8+ T cells by expanding the systemic and intratumoral populations. These findings demonstrate how Vidu alters T-cell biology and supports its continued development, particularly in combination with checkpoint blockade to optimize antitumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0175","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:50:15Z","timestamp":1775825415000},"page":"1006-1019","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic \u03b1PD-1 Activate Tumor-Specific CD8+ T Cells"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-7149","authenticated-orcid":false,"given":"Travis D.","family":"Fischer","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/036jqmy94","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Iowa 1 Cancer Biology Graduate Program, , Iowa City, Iowa."},{"id":[{"id":"https:\/\/ror.org\/036jqmy94","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Iowa 2 Holden Comprehensive Cancer Center, , Iowa City, Iowa."},{"id":[{"id":"https:\/\/ror.org\/036jqmy94","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Iowa 3 Department of Internal Medicine, , Iowa City, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3769-7247","authenticated-orcid":false,"given":"Caitlin D.","family":"Lemke-Miltner","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/036jqmy94","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Iowa 2 Holden Comprehensive Cancer Center, , Iowa City, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-0562","authenticated-orcid":false,"given":"George J.","family":"Weiner","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/036jqmy94","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Iowa 1 Cancer Biology Graduate Program, , Iowa City, Iowa."},{"id":[{"id":"https:\/\/ror.org\/036jqmy94","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Iowa 2 Holden Comprehensive Cancer Center, , Iowa City, Iowa."},{"id":[{"id":"https:\/\/ror.org\/036jqmy94","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Iowa 3 Department of Internal Medicine, , Iowa City, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"2026050101013760000_bib1","doi-asserted-by":"crossref","first-page":"598100","DOI":"10.3389\/fchem.2020.598100","article-title":"Moving beyond the pillars of cancer treatment: perspectives from nanotechnology","volume":"8","author":"Siamof","year":"2020","journal-title":"Front Chem"},{"key":"2026050101013760000_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20892\/j.issn.2095-3941.2017.0086","article-title":"PD-1\/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy","volume":"15","author":"Jia","year":"2018","journal-title":"Cancer Biol Med"},{"key":"2026050101013760000_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"2026050101013760000_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2026050101013760000_bib5","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050101013760000_bib6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2026050101013760000_bib7","doi-asserted-by":"crossref","first-page":"9912188","DOI":"10.1155\/2021\/9912188","article-title":"Toll-like receptor-based strategies for cancer immunotherapy","volume":"2021","author":"Pahlavanneshan","year":"2021","journal-title":"J Immunol Res"},{"key":"2026050101013760000_bib8","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1\u201310 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J Immunol"},{"key":"2026050101013760000_bib9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.1900742","article-title":"Antibody opsonization of a TLR9 agonist-containing virus-like particle enhances in situ immunization","volume":"204","author":"Lemke-Miltner","year":"2020","journal-title":"J Immunol"},{"key":"2026050101013760000_bib10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3390\/vaccines9090982","article-title":"Monocytes exposed to immune complexes reduce pDC type 1 interferon response to vidutolimod","volume":"9","author":"Sabree","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2026050101013760000_bib11","doi-asserted-by":"crossref","first-page":"1769287","DOI":"10.3389\/fimmu.2026.1769287","article-title":"BDCA2 plays a central role in the binding, internalization and response of plasmacytoid dendritic cells to vidutolimod","volume":"17","author":"Lemke-Miltner","year":"2026","journal-title":"Front Immunol"},{"key":"2026050101013760000_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/eji.201142064","article-title":"Virus-like particles induce robust human T-helper cell responses","volume":"42","author":"Braun","year":"2012","journal-title":"Eur J Immunol"},{"key":"2026050101013760000_bib13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res"},{"key":"2026050101013760000_bib14","doi-asserted-by":"crossref","first-page":"e70022","DOI":"10.1002\/cncr.70022","article-title":"Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: final analysis from a phase 1b study","volume":"131","author":"Milhem","year":"2025","journal-title":"Cancer"},{"key":"2026050101013760000_bib15","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"2026050101013760000_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front Immunol"},{"key":"2026050101013760000_bib17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"2026050101013760000_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026050101013760000_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u201cT cell exhaustion\u201d","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2026050101013760000_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"2026050101013760000_bib21","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1158\/1078-0432.CCR-21-0206","article-title":"CD4 T-cell exhaustion: does it exist and what are its roles in cancer?","volume":"27","author":"Miggelbrink","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026050101013760000_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"2026050101013760000_bib23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41590-019-0528-5","article-title":"Author Correction: subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"2026050101013760000_bib24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"2026050101013760000_bib25","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1182\/blood-2009-02-206557","article-title":"Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity","volume":"113","author":"Almeida","year":"2009","journal-title":"Blood"},{"key":"2026050101013760000_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"2026050101013760000_bib27","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory","volume":"37","author":"Doering","year":"2012","journal-title":"Immunity"},{"key":"2026050101013760000_bib28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"2026050101013760000_bib29","doi-asserted-by":"crossref","first-page":"e1008555","DOI":"10.1371\/journal.ppat.1008555","article-title":"Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation","volume":"16","author":"Zhao","year":"2020","journal-title":"PLoS Pathog"},{"key":"2026050101013760000_bib30","doi-asserted-by":"crossref","first-page":"e000940","DOI":"10.1136\/jitc-2020-000940","article-title":"In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy","volume":"8","author":"Cheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026050101013760000_bib31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"2026050101013760000_bib32","doi-asserted-by":"crossref","first-page":"10050","DOI":"10.1128\/JVI.01692-16","article-title":"Cell-cell sensing of viral infection by plasmacytoid dendritic cells","volume":"90","author":"Webster","year":"2016","journal-title":"J Virol"},{"key":"2026050101013760000_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1471-4906(02)02259-7","article-title":"Of mice and men: species variations of Toll-like receptor expression","volume":"23","author":"Rehli","year":"2002","journal-title":"Trends Immunol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0175\/3766122\/crc-26-0175.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1006\/3784599\/crc-26-0175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1006\/3784599\/crc-26-0175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:01:46Z","timestamp":1777611706000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/5\/1006\/784505\/Intratumoral-Virus-Like-Particles-Containing-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0175","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32697872","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697875","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697863","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697866","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697854","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697821","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697836","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697869","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697848","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697827","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697860","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8541923","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}